Blockage of RANKL or RANK either systemically or specifically in the liver of T2DM mouse models leads to a significant improvement of hepatic insulin sensitivity, plasma glucose concentrations, and glucose tolerance. This evidence concerns the gene TNFRSF11A and type 2 diabetes mellitus.